Registration effective
Open the filing on sec.gov
BioAtla, Inc. (BCAB)
OTC: BCAB · Biological Products, (No Diagnostic Substances) · San Diego, CA · filing with the SEC since 2020
The companyfiscal 2021, as filed
Revenue$300,000
Net income-$95.4M-166.1%
Earnings per share$-2.76
Operating cash flow-$62.2M-71.2%
Cash$245M+2.7%
Debtn/a
Shareholders’ equity$211M+0.4%
Shares, diluted34.6M
Return on equity-164.7%
The recordfrom its filings
Filings in 202645
Newest filingOct 29 · EFFECT
Annual reportMar 31, 2026
Quarterly reportAug 13, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted46
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Jun 2026Net income -$31.5MCash from operations -$23.5Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Shelf offering
Open the filing on sec.gov
Registration withdrawal request
Open the filing on sec.gov
Listing registration
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.